Next Article in Journal
Sphingolipid Metabolism in Glioblastoma and Metastatic Brain Tumors: A Review of Sphingomyelinases and Sphingosine-1-Phosphate
Next Article in Special Issue
The c.*52 A/G and c.*773 A/G Genetic Variants in the UTR′3 of the LDLR Gene Are Associated with the Risk of Acute Coronary Syndrome and Lower Plasma HDL-Cholesterol Concentration
Previous Article in Journal
MiRNA Profiles of Extracellular Vesicles Secreted by Mesenchymal Stromal Cells—Can They Predict Potential Off-Target Effects?
Previous Article in Special Issue
Galectin-3: A Potential Prognostic and Diagnostic Marker for Heart Disease and Detection of Early Stage Pathology
Open AccessReview

Circulating microRNA as a Biomarker for Coronary Artery Disease

Faculty of Health and Medical Science, University of Surrey, Guildford GU2 7AL, UK
School of Clinical Medicine, University of Cambridge, Cambridge CB2 1TN, UK
School of Medicine, University Malaysia Sarawak, Kota Samarahan 94300, Sarawak, Malaysia
Author to whom correspondence should be addressed.
Biomolecules 2020, 10(10), 1354;
Received: 7 August 2020 / Revised: 15 September 2020 / Accepted: 19 September 2020 / Published: 23 September 2020
(This article belongs to the Special Issue Molecular Biomarkers In Cardiology)
Coronary artery disease (CAD) is the leading cause of sudden cardiac death in adults, and new methods of predicting disease and risk-stratifying patients will help guide intervention in order to reduce this burden. Current CAD detection involves multiple modalities, but the consideration of other biomarkers will help improve reliability. The aim of this narrative review is to help researchers and clinicians appreciate the growing relevance of miRNA in CAD and its potential as a biomarker, and also to suggest useful miRNA that may be targets for future study. We sourced information from several databases, namely PubMed, Scopus, and Google Scholar, when collating evidentiary information. MicroRNAs (miRNA) are short, noncoding RNAs that are relevant in cardiovascular physiology and pathophysiology, playing roles in cardiac hypertrophy, maintenance of vascular tone, and responses to vascular injury. CAD is associated with changes in miRNA expression profiles, and so are its risk factors, such as abnormal lipid metabolism and inflammation. Thus, they may potentially be biomarkers of CAD. Nevertheless, there are limitations in using miRNA. These include cost and the presence of several confounding factors that may affect miRNA profiles. Furthermore, there is difficulty in the normalisation of miRNA values between published studies, due to pre-analytical variations in samples. View Full-Text
Keywords: coronary artery disease; biomarkers; noncoding RNA; microRNA coronary artery disease; biomarkers; noncoding RNA; microRNA
Show Figures

Graphical abstract

MDPI and ACS Style

Fazmin, I.T.; Achercouk, Z.; Edling, C.E.; Said, A.; Jeevaratnam, K. Circulating microRNA as a Biomarker for Coronary Artery Disease. Biomolecules 2020, 10, 1354.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop